Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
2023 · Signal Transduction and Targeted Therapy · 266 citations
https://doi.org/10.1038/s41392-022-01235-0
H
Huanzhang Niu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
25
Papers
361
Citations
5
h-index
5
i10-index
Huanzhang Niu is an academic researcher from Henan University of Science and Technology. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease and Transplantation & Liver Disease Diagnosis and Treatment. The author has an h-index of 5, co-authored 22 publications.
Papers by this author
worksDynamic changes in liver function after transjugular intrahepatic portosystemic shunt in patients with cirrhosis
2022 · Journal of interventional medicine · 5 citations
https://doi.org/10.1016/j.jimed.2022.09.001
Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
2023 · Heliyon · 3 citations
https://doi.org/10.1016/j.heliyon.2023.e23455
Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma
2025 · Cancer Cell International · 2 citations
https://doi.org/10.1186/s12935-025-03923-7
Association between overt hepatic encephalopathy and liver pathology after transjugular intrahepatic portosystemic shunt creation in cirrhotic patients
2025 · Scientific Reports · 0 citations
https://doi.org/10.1038/s41598-025-86176-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat